TC Biopharm (Holdings) Plc (TCBP) |
|
0.385 0.004 (1.05%)
|
09-27 15:58 |
|
Open: |
0.381 |
Pre. Close: |
0.381 |
|
High:
|
0.4099 |
Low:
|
0.38 |
|
Volume:
|
109,640 |
Market Cap:
|
3(M) |
|
|
|
Technical analysis |
as of: 2023-09-27 4:22:26 PM |
|
Short-term rate:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
|
Mid-term rate:
|
  |
| Target: |
Six months: 0.62 One year: 0.75 |
| Support: |
Support1: 0.34 Support2: 0.29 |
| Resistance: |
Resistance1: 0.53 Resistance2: 0.64 |
| Pivot: |
0.45  |
| Moving Average: |
MA(5): 0.39 MA(20): 0.47
MA(100): 0.6 MA(250): 3.5 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1 |
| Stochastic oscillator: |
%K(14,3): 10.4 %D(3): 9.1 |
| RSI: |
RSI(14): 32.8 |
| 52-week: |
High: 15.5 Low: 0.34 |
| Average Vol(K): |
3-Month: 665 (K) 10-Days: 140 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.[ TCBP ] has closed above bottom band by 11.8%. Bollinger Bands are 37.1% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
0.41 - 0.41 |
0.41 - 0.42 |
|
Low:
|
0.37 - 0.38 |
0.38 - 0.38 |
|
Close:
|
0.38 - 0.38 |
0.38 - 0.38 |
|
Company Description |
|
TC Biopharm (Holdings) Plc, a clinical-stage biopharmaceutical company, focuses on developing immunotherapy products based on its allogeneic gamma delta T cell platform. Its product pipeline includes OmnImmune, an unmodified cell therapy used in the treatment of acute myeloid leukemia; and ImmuniStim, an unmodified cell therapy to treat COVID-19. The company was founded in 2013 and is headquartered in Motherwell, the United Kingdom. |
Headline News |
Wed, 27 Sep 2023
TC BioPharm to Present at the LD Micro Main Event XVI - WV News
Wed, 27 Sep 2023
TC BioPharm to Present at the LD Micro Main Event XVI - PR Newswire
Tue, 05 Sep 2023
TC BioPharm Announces Grant Funding in Collaboration with ... - PR Newswire
Tue, 29 Aug 2023
Why Alpha Tau Medical Shares Are Trading Higher By Over 8 ... - Investing.com UK
Tue, 29 Aug 2023
TC BioPharm to Present at H.C. Wainwright 25th Annual Global ... - PR Newswire
Mon, 31 Jul 2023
TC BioPharm Maintains Nasdaq Listing - TC BioPharm (Holdings) (NASDAQ:TCBP) - Benzinga
|
Financial Analysis |
| Price to Book Value: |
Neutral |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Neutral |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Neutral |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Neutral |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Neutral |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Biotechnology |
| Shares Out. |
7 (M) |
| Shares Float |
2 (M) |
|
% Held by Insiders
|
11.7 (%) |
|
% Held by Institutions
|
5.2 (%) |
|
Shares Short
|
35 (K) |
|
Shares Short P.Month
|
88 (K) |
Stock Financials |
|
EPS
|
-2.2 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
-0.03 |
|
Profit Margin (%)
|
-36.2 |
|
Operating Margin (%)
|
-310.1 |
|
Return on Assets (ttm)
|
-78.6 |
|
Return on Equity (ttm)
|
0 |
|
Qtrly Rev. Growth
|
188.6 |
|
Gross Profit (p.s.)
|
0.52 |
|
Sales Per Share
|
0.52 |
|
EBITDA (p.s.)
|
-1.54 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-15 (M) |
|
Levered Free Cash Flow
|
-8 (M) |
Stock Valuations |
|
PE Ratio
|
-0.18 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
-12.71 |
|
Price to Sales
|
0.72 |
|
Price to Cash Flow
|
-0.2 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
Your Ad Here
|
|
